You just read:

Nordic Nanovector to Present Preclinical Studies With 212Pb-NNV003, a Novel CD37-specific Targeted Alpha Therapy for CLL and NHL, at TRP 2019

News provided by

Nordic Nanovector

06 Jun, 2019, 06:16 BST